期刊论文详细信息
BMC Nephrology
Hypertension and the development of New onset chronic kidney disease over a 10 year period: a retrospective cohort study in a primary care setting in Malaysia
Siew Mooi Ching1  Yook Chin Chia2 
[1] Department of Family Medicine,Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, 43400, Malaysia;Curtin Health Innovation Research Institute, Faculty of Health Sciences, University of Curtin, GPO Box U1987, Perth, Western Australia 6845, Australia
关键词: Cohort, Malaysia;    Estimated glomerular filtration rate;    Primary care;    Chronic kidney disease;    Hypertension;   
Others  :  1083039
DOI  :  10.1186/1471-2369-13-173
 received in 2012-08-01, accepted in 2012-12-19,  发布年份 2012
PDF
【 摘 要 】

Background

Little is known about the rate of progression to chronic kidney disease (CKD) among hypertensive patients, particularly at the primary care level. This study aims to examine risk factors associated with new onset CKD among hypertensive patients attending a primary care clinic.

Methods

This is a 10-year retrospective cohort study of 460 patients with hypertension who were on treatment. Patient information was collected from patient records. CKD was defined as a glomerular filtration rate <60 ml/min per 1.73 m2 (Cockcroft-Gault equation). Multiple logistic regression statistics was used to test the association in newly diagnosed CKD.

Results

The incidence of new CKD was 30.9% (n = 142) with an annual rate of 3%. In multivariate logistic regression analysis, factors associated with development of new onset of CKD among hypertensive patients were older age (odds ratio [OR] 1.123, 95% confidence interval [CI] 1.078-1.169), presence of diabetes (OR 2.621, 95% CI 1.490-4.608), lower baseline eGFR (OR 1.041, 95% CI 0.943-0.979) and baseline hyperuricaemia (OR 1.004, 95% CI 1.001-1.007).

Conclusions

The progression to new onset CKD is high among urban multiethnic hypertensive patients in a primary care population. Hence every effort is needed to detect the presence of new onset CKD earlier. Hypertensive patients who are older, with underlying diabetes, hyperuricaemia and lower baseline eGFR are associated with the development of CKD in this population.

【 授权许可】

   
2012 Chia and Ching; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20141224193352704.pdf 183KB PDF download
【 参考文献 】
  • [1]Jha V: Current Status of Chronic Kidney Disease Care in Southeast Asia. Semin Nephrol 2009, 29(5):487-496.
  • [2]El Nahas AM, Bello AK: Chronic kidney disease: the global challenge. Lancet 2005, 365(9456):331-340.
  • [3]Sabanayagam C, Shankar A, Lim SC, Tai ES, Wong TY: Hypertension, hypertension control, and chronic kidney disease in a Malay population in Singapore. Asia-Pac J Public He 2011, 23(6):936-945.
  • [4]Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J: Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003, 14(11):2934-2941.
  • [5]Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al.: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139(2):137.
  • [6]Barri YM: Hypertension and kidney disease: a deadly connection. Curr Cardiol Rep 2006, 8:411-417.
  • [7]Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, et al.: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108(17):2154-2169.
  • [8]Lenfant C, Chobanian AV, Jones DW, Roccella EJ: Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Circulation 2003, 107(24):2993-2994.
  • [9]Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, Locatelli F, MacLeod A, Vanholder R, Walker R, et al.: The burden of kidney disease: improving global outcomes. Kidney Int 2004, 66(4):1310-1314.
  • [10]Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, Jindal K, Mendelssohn D, Tobe S, Singer J, et al.: Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 2001, 38(6):1398-1407.
  • [11]Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351(13):1296-1305.
  • [12]Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375(9731):2073-2081.
  • [13]Hanratty R, Chonchol M, Miriam Dickinson L, Beaty BL, Estacio RO, Mackenzie TD, Hurley LP, Linas SL, Steiner JF, Havranek EP: Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension. Nephrol Dial Transplant 2010, 25(3):801-807.
  • [14]Lindeman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985, 33(4):278.
  • [15]Stevens Lesley A, Coresh J, Greene T, Levey Andrew S: Assessing Kidney Function-Measured and Estimated Glomerular Filtration Rate. N Engl J Med 2006, 354(23):2473-2483.
  • [16]Freedman BI, Sedor JR: Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008, 19(11):2047-2051.
  • [17]Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334(1):13-18.
  • [18]Ravera M, Re M, Deferrari L, Vettoretti S, Deferrari G: Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol 2006, 17(4 suppl 2):S98-S103.
  • [19]Fonseca V, Clark NG: Standards of medical care in diabetes. Diabetes Care 2006, 29(2):476-477.
  • [20]Chia Yook C, Ching Siew M: Concordance of Serum Creatinine to Estimated Glomerular Filtration Rate in Determining Early Chronic Kidney Disease in Malaysia. Life Science Journal 2012, 9(3):453-457.
  • [21]Poggio ED, Wang X, Greene T, Van Lente F, Hall PM: Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault Equations in the Estimation of GFR in Health and in Chronic Kidney Disease. J Am Soc Nephrol 2005, 16(2):459-466.
  • [22]Swedko PJ, Clark HD, Paramsothy K, Akbari A: Serum Creatinine Is an Inadequate Screening Test for Renal Failure in Elderly Patients. Arch Intern Med 2003, 163(3):356-360.
  • [23]Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine [abstract]. Nephron 1976, 16(1):31.
  • [24]Leoncini G, Viazzi F, Rosei EA, Ambrosioni E, Costa FV, Leonetti G, Pessina AC, Trimarco B, Volpe M, Deferrari G, et al.: Chronic kidney disease in hypertension under specialist care: the I-DEMAND study. J Hypertens 2010, 28(1):156-162.
  • [25]Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, et al.: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003, 63(4):1499-1507.
  • [26]Lewis EJ: The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes [abstract]. Am J Hypertens 2002, 15:s123-s128.
  • [27]Van der Meer V, Wielders HP, Grootendorst DC, de Kanter JS, Sijpkens YW, Assendelft WJ, Gussekloo J, Dekker FW, Groeneveld Y: Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice. Br J Gen Pract 2010, 60(581):884-890.
  • [28]Duarte D, Santos Araujo C, Leite-Moreira AF: Hypertension and angiogenesis in the aging kidney: A review. Arch Gerontol Geriatr 2011, 52(3):e93-e102.
  • [29]Bangstad HJ, Seljeflot I, Berg T, Hanssen K: Renal tubulointerstitial expansion is associated with endothelial dysfunction and inflammation in type 1 diabetes. Scand J Clin Lab Invest 2009, 69(1):138-144.
  • [30]Phillips AO, Steadman R: Diabetic nephropathy: the central role of renal proximal tubular cells in tubulointerstitial injury. Histol Histopathol 2002, 17(1):247-252.
  • [31]Mogensen CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed) 1982, 285(6343):685-688.
  • [32]Parving HH, Andersen AR, Smidt UM, Svendsen PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983, 1(8335):1175-1179.
  • [33]Viberti GC, Bilous RW, Mackintosh D, Keen H: Monitoring glomerular function in diabetic nephropathy. A prospective study. Am J Med 1983, 74(2):256-264.
  • [34]Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995, 155(10):1073-1080.
  • [35]Mogensen CE: Diabetic Renal Disease: The Quest for Normotension—and Beyond. Diabetic Med 1995, 12(9):756-769.
  • [36]Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF: Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007, 50(2):239-247.
  • [37]Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F: Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol 2008, 43(4):347-352.
  • [38]Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008, 359(17):1811-1821.
  • [39]Kang D-H, Chen W: Uric Acid and Chronic Kidney Disease: New Understanding of an Old Problem. Semin Nephrol 2011, 31(5):447-452.
  • [40]Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, Arroyo D, Luno J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010, 5(8):1388-1393.
  • [41]Siu YP, Leung KT, Tong MKH, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006, 47(1):51-59.
  • [42]Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358(15):1547-1559.
  • [43]Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, Narita M, Koyama A: Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007, 71(2):159-166.
  • [44]Iseki K, Ikemiya Y, Iseki C, Takishita S: Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003, 63(4):1468-1474.
  • [45]Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, Smith E: Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 2008, 155(5):791-805.
  • [46]Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, Rahman M, Deysher AE, Zhang YL, Schmid CH, et al.: Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 2007, 18(10):2749-2757.
  文献评价指标  
  下载次数:11次 浏览次数:20次